MiR-199b-5p targets HER2 in breast cancer cells

Authors

  • Chen Fang,

    1. Department of Biochemical Pharmacy, School of Pharmacy, Second Military Medical University, Shanghai 200433, China
    Search for more papers by this author
  • Yu Zhao,

    1. Shanghai Key Laboratory of Gastric Neoplasms, Department of Surgery, Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
    Search for more papers by this author
  • Baoyu Guo

    Corresponding author
    1. Department of Biochemical Pharmacy, School of Pharmacy, Second Military Medical University, Shanghai 200433, China
    • Department of Biochemical Pharmacy, School of Pharmacy, Second Military Medical University, Shanghai 200433, China.
    Search for more papers by this author

  • Conflict of interest: nothing to declare.

  • Chen Fang and Yu Zhao contributed equally to this work.

Abstract

HER2 (ErbB2) has been reported to be overexpressed in 20–30% of breast cancer and confers poor survival because of high proliferation and metastasis rates. MicroRNAs are small noncoding RNAs that are responsible for the post-transcriptional regulation of target genes. We found miR-199b-5p inhibited HER2 expression by direct targeting its 3′-untranslated region (3′UTR) in breast cancer cells. In addition, miR-199b-5p inhibited HER2 downstream signaling by ERK1/2 and AKT pathways in breast cancer cells. Besides, transwell migration, wound healing, and clonogenicity were obviously inhibited by overexpression of miR-199b-5p in HER2-positive breast cancer cells. We also found that miR-199b-5p could enhance the suppression of trastuzumab on cell migration and clonogenicity. These results suggest that miR-199b-5p may have the potential to be a novel important alternative therapeutic target for HER2-positive breast cancer. J. Cell. Biochem. 114: 1457–1463, 2013. © 2013 Wiley Periodicals, Inc.

Ancillary